Drug intelligence / Profile preview

il-1β siRNA

Development stage
Preclinical
Lead developer
University of Texas MD Anderson Cancer Center
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous
01

Overview

il-1β siRNA is a small interfering RNA (siRNA) designed to silence the expression of interleukin-1 beta (IL-1β), a potent pro-inflammatory cytokine. In the context of oncology research, particularly melanoma, IL-1β is often aberrantly expressed and contributes to chronic inflammation, oxidative stress, and tumor progression. By utilizing the RNA interference (RNAi) pathway, this siRNA targets IL-1β mRNA for degradation, thereby inhibiting the production of the cytokine. Research in melanoma cell lines (such as A375 and WM793) has shown that knockdown of IL-1β leads to significant decreases in inflammatory markers like Cox-2, reduced reactive oxygen species, and suppression of cell growth through the induction of autophagy and upregulation of tumor suppressors p53 and p21.

Other names
interleukin-1 beta siRNAinterleukin1 beta siRNAinterleukin 1 beta siRNAIL-1B siRNAIL1B siRNAIL 1B siRNAIL-1 beta siRNAIL1 beta siRNAIL 1 beta siRNA
02

Targets

Innate immune RNA sensorsInterleukin-1 beta messenger RNA

Beyond the preview

Go deeper on il-1β siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on il-1β siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call